- TRADE NAME: Fasenra (AstraZeneca)
- INDICATIONS: Add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype
- CLASS: Interleukin-5 antagonist, Monoclonal antibody
- HALF-LIFE: 15 days
- FDA APPROVAL DATE: 11/14/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Insufficient evidence to inform on drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
